Gilead Sciences (GILD) Announces Marketing Authorization for Yeytuo from the European Commission

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top most undervalued low volatility stocks to buy now. On August 26, Gilead Sciences, Inc. (NASDAQ:GILD) announced that it attained marketing authorization for Yeytuo (lenacapavir) from the European Commission (EC).

Yeytuo is the company’s twice-yearly injectable HIV-1 capsid inhibitor that is used as “pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35kg”.

Management reported that Yeytuo is the first and only twice-yearly PrEP option to be approved for use in the 27 member states of the European Union, including Iceland, Norway, and Liechtenstein.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19.

Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 countries.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.